Where does Horizon Therapeutics USA, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Horizon Therapeutics USA, Inc. ranks #35,723 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Horizon Therapeutics USA, Inc. hold?

Horizon Therapeutics USA, Inc. holds 7 US utility patents granted between 2022 and 2025, spanning 5 technology areas.

What is Horizon Therapeutics USA, Inc.'s Innovation Score?

Horizon Therapeutics USA, Inc. has an Innovation Score of 43.5 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Horizon Therapeutics USA, Inc. focus on?

Horizon Therapeutics USA, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents, ranking #2,588 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Horizon Therapeutics USA, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Horizon Therapeutics USA, Inc..

What does claim depth mean for Horizon Therapeutics USA, Inc.'s patents?

Horizon Therapeutics USA, Inc.'s patents average 14.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Horizon Therapeutics USA, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Horizon Therapeutics USA, Inc.

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Horizon ranks #35,723 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.

#35,723
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.5/100): 14.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R35723 · US Corporation #35,723 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #35,723/49,997
PHOTO-FINISH HiveIO
CPC-NARROW A61P · 5 areas
INNOV-PAR 43.5/100
CLAIMS-RICH 14.0 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: HiveIO Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Horizon’s 43.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (17%) Velocity 20.0 pts (46%) Breadth 7.9 pts (18%) Claim depth 8.4 pts (19%)

Qualcomm Incorporated · highest

85
Horizon Therapeutics… · this assignee

43
3D Lighting… · lowest

7

What this shows Horizon's Innovation Score is 43.5/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Horizon?

Each dot is one of Horizon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Horizon’s own 14.0 claims/patent is at or below the 18.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Horizon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Horizon's grants concentrate

Horizon Therapeutics USA, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2022. By volume, Horizon sits between HiveIO Inc. and Hotberry, LLC.

Horizon's three-year grant acceleration

Horizon Therapeutics USA, Inc. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Hiveio

7
Hobie Cat IP

7
Hola Networks

7
Hopgrade

7
Horning Manufactu…

7
Horst Siedle & KG

7
Hotstart

7
Hotberry

7
Horizon Therapeut… ◀

7

What this shows Horizon holds 7 patents at rank #35,746, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Horizon

By rank, the assignees closest to #35,746 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Horizon's primary technology class.

Horizon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Horizon Therapeutics USA, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	1	14.3%
2023	3	42.9%
2024	2	28.6%
2025partial year	1	14.3%

Which technologies does Horizon Therapeutics USA, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C12Y - Enzymes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Horizon Therapeutics USA, Inc.'s patent record in context - here's where to go next.

Horizon Therapeutics USA, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #35,723 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Horizon Therapeutics USA, Inc. against HiveIO Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.